Amélie Boichard - Search Results

Year	Number of Results
2014	3
2016	3
2017	3
2018	5
2019	2
2020	8
2021	2
2022	2
2023	0

1

New therapeutic approaches to overcoming resistant EGFR exon 20 alterations.

Li AM, Boichard A, Felip E, Kurzrock R. Li AM, et al. Among authors: boichard a. Crit Rev Oncol Hematol. 2020 Jul;151:102990. doi: 10.1016/j.critrevonc.2020.102990. Epub 2020 May 20. Crit Rev Oncol Hematol. 2020. PMID: 32485428 Free PMC article. Review.

2

Genomes in the clinic: the Gustave Roussy Cancer Center experience.

Lacroix L, Boichard A, André F, Soria JC. Lacroix L, et al. Among authors: boichard a. Curr Opin Genet Dev. 2014 Feb;24:99-106. doi: 10.1016/j.gde.2013.11.013. Epub 2014 Feb 26. Curr Opin Genet Dev. 2014. PMID: 24583392 Review.

3

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting.

Joshi RS, Boichard A, Adashek JJ, Kurzrock R. Joshi RS, et al. Among authors: boichard a. Cancer Biol Ther. 2022 Dec 31;23(1):1-6. doi: 10.1080/15384047.2022.2128608. Cancer Biol Ther. 2022. PMID: 36171565 Free PMC article.

4

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy.

Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Frampton GM, Tsigelny IF, Kurzrock R. Boichard A, et al. Oncoimmunology. 2018 Dec 24;8(3):1550341. doi: 10.1080/2162402X.2018.1550341. eCollection 2019. Oncoimmunology. 2018. PMID: 30723579 Free PMC article.

5

Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden.

Boichard A, Lippman SM, Kurzrock R. Boichard A, et al. J Hematol Oncol. 2021 Dec 2;14(1):201. doi: 10.1186/s13045-021-01211-1. J Hematol Oncol. 2021. PMID: 34857015 Free PMC article.

6

Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.

Boichard A, Wagner MJ, Kurzrock R. Boichard A, et al. Genome Med. 2020 Jul 9;12(1):61. doi: 10.1186/s13073-020-00753-2. Genome Med. 2020. PMID: 32646514 Free PMC article.

7

Variable Mutation Expression in Human Cancers: A "Hide-and-Seek" Mechanism Linked to Differential MHC-I Presentation Dynamics.

Boichard A, Kurzrock R. Boichard A, et al. Mol Cancer Ther. 2022 Jul 5;21(7):1219-1226. doi: 10.1158/1535-7163.MCT-21-0831. Mol Cancer Ther. 2022. PMID: 35545005

8

RET mutation and increased angiogenesis in medullary thyroid carcinomas.

Verrienti A, Tallini G, Colato C, Boichard A, Checquolo S, Pecce V, Sponziello M, Rosignolo F, de Biase D, Rhoden K, Casadei GP, Russo D, Visani M, Acquaviva G, Ferdeghini M, Filetti S, Durante C. Verrienti A, et al. Among authors: boichard a. Endocr Relat Cancer. 2016 Aug;23(8):665-76. doi: 10.1530/ERC-16-0132. Epub 2016 Jul 8. Endocr Relat Cancer. 2016. PMID: 27402614

9

BRAF mutation as a novel driver of eosinophilic cystitis.

Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R. Choi MY, et al. Among authors: boichard a. Cancer Biol Ther. 2017 Sep 2;18(9):655-659. doi: 10.1080/15384047.2017.1360449. Epub 2017 Aug 22. Cancer Biol Ther. 2017. PMID: 28829677 Free PMC article.

10

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.

Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Goodman AM, et al. Among authors: boichard a. Oncoimmunology. 2017 Dec 22;7(3):e1404217. doi: 10.1080/2162402X.2017.1404217. eCollection 2018. Oncoimmunology. 2017. PMID: 29399405 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

25 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year